• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Ankylosing Spondylitis News / Is TNF Inhibitor Therapy Effective at Preventing Bony Ankylosis in Ankylosing Spondylitis?

Is TNF Inhibitor Therapy Effective at Preventing Bony Ankylosis in Ankylosing Spondylitis?

February 24, 2007 By Arthritis Center

TNF-α blockade in patients with ankylosing spondylitis (AS) has been shown to improve clinical symptoms of disease and physical function.  However, a benefit in reducing the incidence or severity of axial ankylosis has not been demonstrated.  In fact, qualified observational data has suggested that radiographic progression of ankylosis and inflammation may be unrelated in AS.  Here, Lories et al (Arthritis Rheum 2007; 56(2): 489) examine the relationship between TNF-α inhibition and joint ankylosis in a mouse model of AS.

Methods and Results

Experiment 1: In order to test the effect of anti-TNF therapy on inflammatory arthritis in mice, inflammatory arthritis was induced by articular injection of bovine serum albumin (BSA) and IL-1.  In this group, a single injection of etanercept was administered four days after the induction of arthritis.  Compared to untreated mice, mice treated with etanercept had significantly reduced TNF-α expression, joint inflammation, pannus formation, and bone and cartilage destruction.

Experiment 2: In order to test the effect of anti-TNF therapy on spontaneous arthritis, male mice prone to developing an AS-like disease were treated with twice weekly etanercept starting at 12 weeks of age or placebo and followed for the development of spontaneous arthritis.  In this setting, there were no qualitative or quantitative differences in the incidence or severity of arthritis.  Histologically, chondrogenesis, bony proliferation, and ankylosis were not statistically different in etanercept treated vs. placebo treated mice, despite the expression of TNF-α in regions of enthesial inflammation and damage.  Etanercept antibodies were common, but did not affect the ability of etanercept to inhibit TNF-α.  Bone morphogenic protein (BMP) and Smad signaling, steps involved in early chondrogenesis, were unaffected by etanercept therapy.

Experiment 3: In an in vitro model of enthesial chondrogenesis, TBF-β and BMP induced chondrogenesis was inhibited by the presence of TNF-α.  Osteogenesis was not affected by TNF-α.

Conclusions

Although effective in reducing inflammation and improving signs and symptoms of inflammatory synovitis, etanercept was ineffective at reducing enthesitis or subsequent ankylosis.  Maximal inhibition of these processes may actually require the presence of TNF-α.

Editorial Comment

These are very compelling findings which suggest that the processes of acute inflammation and ongoing structural damage may be independent in AS.  It is discouraging to imagine that therapies effective in treating the signs and symptoms of AS and related axial arthropathies may have no long term effect on structural progression.  Indeed, these results suggest that TNF-α may actually be protective against some forms of longterm damage, and that blocking TNF-α could result in more, rather than less, structural progression.  However, to date, there is no evidence to confirm these preliminary findings in humans.  Longer term follow-up of radiographic outcomes from clinical trials data is needed to more carefully address these concerns.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy